Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393613 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
A Phase 3 study of Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 674
- Enrollment target
- 20
- Study locations
NCT01393613 is a Phase 3 study of Acute Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 674 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01393613, a Phase 3 study of Acute Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 674 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG OPC-34712
Study Locations (20)
California
- - Escondido
- - Long Beach
- - Orange
- - Pico Rivera
- - San Diego
Texas
- - Austin
- - Dallas
- - Houston
Arkansas
- - Little Rock
- - Springdale
Florida
- - North Miami
- - North Miami
Louisiana
- - Lake Charles
- - Shreveport
Kansas
- - Overland Park
Mississippi
- - Flowood
Missouri
- - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393613
The ClinicalTrials.gov registry entry for NCT01393613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 674 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01393613 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01393613 about?
NCT01393613 is a clinical study titled "Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia". The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.
What is the current status of trial NCT01393613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 674 participants. The study started on 2011-07. Estimated completion is 2014-02.
What conditions does trial NCT01393613 study?
This clinical trial studies the following conditions: Acute Schizophrenia.
What interventions are being tested in trial NCT01393613?
The interventions under investigation include: Placebo (DRUG), OPC-34712 (DRUG).
Who is sponsoring clinical trial NCT01393613?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01393613 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.